Hepion Pharmaceuticals, Inc. Stock price

Equities

HEPA

US4268973025

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.49 USD -0.40% Intraday chart for Hepion Pharmaceuticals, Inc. +7.33% -23.15%
Sales 2023 * - Sales 2024 * - Capitalization 10.8M
Net income 2023 * -43M Net income 2024 * -51M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.23 x
P/E ratio 2024 *
-0.23 x
Employees 25
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.73%
More Fundamentals * Assessed data
Dynamic Chart
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors CI
Hepion Pharmaceuticals, Inc. Announces Board Changes CI
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors CI
North American Morning Briefing : Futures Pause -2- DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process MT
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice CI
Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding CI
Hepion Pharmaceuticals, Inc. announced that it expects to receive $5.000004 million in funding CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat CI
Aurinia Pharmaceuticals Appoints Robert Foster as Part of Deal With Shareholder MKT Capital MT
More news
1 day-0.40%
1 week+7.33%
Current month-16.16%
1 month-9.78%
3 months-25.89%
6 months-48.61%
Current year-23.15%
More quotes
1 week
2.21
Extreme 2.21
2.56
1 month
1.89
Extreme 1.89
3.33
Current year
1.49
Extreme 1.49
3.49
1 year
1.49
Extreme 1.49
20.66
3 years
1.49
Extreme 1.49
46.37
5 years
1.49
Extreme 1.49
476.00
10 years
1.49
Extreme 1.49
70 336.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 15-12-31
Chief Tech/Sci/R&D Officer - 19-10-02
Chief Operating Officer - 22-06-13
Members of the board TitleAgeSince
Chairman 76 13-05-14
Director/Board Member 69 13-11-25
Director/Board Member 45 22-06-26
More insiders
Date Price Change Volume
24-03-28 2.49 -0.40% 21,291
24-03-27 2.5 +7.76% 51,687
24-03-26 2.32 +3.11% 32,817
24-03-25 2.25 -4.26% 8,445
24-03-22 2.35 +1.29% 25,902

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Hepion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company's rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.49 USD
Average target price
30 USD
Spread / Average Target
+1,104.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Hepion Pharmaceuticals, Inc. - Nasdaq